Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Bicara Therapeutics Inc (NASDAQ: BCAX) closed the day trading at $9.25 down -2.01% from the previous closing price of $9.44. In other words, the price has decreased by -$2.01 from its previous closing price. On the day, 0.63 million shares were traded.
Ratios:
For a better understanding of BCAX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 24.62 and its Current Ratio is at 24.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On April 17, 2025, Wells Fargo started tracking the stock assigning a Underweight rating and target price of $8.
On February 06, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $31.Wedbush initiated its Outperform rating on February 06, 2025, with a $31 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 14 ’25 when Meisner Lara sold 79,146 shares for $12.90 per share. The transaction valued at 1,021,211 led to the insider holds 0 shares of the business.
LARA S. MEISNER bought 79,146 shares of BCAX for $1,056,599 on Mar 14 ’25. On Sep 16 ’24, another insider, RA CAPITAL MANAGEMENT, L.P., who serves as the Director of the company, bought 1,833,000 shares for $18.00 each. As a result, the insider paid 32,994,000 and bolstered with 4,303,418 shares of the company.
Stock Price History:
Over the past 52 weeks, BCAX has reached a high of $28.09, while it has fallen to a 52-week low of $7.80. The 50-Day Moving Average of the stock is -27.65%, while the 200-Day Moving Average is calculated to be -44.52%.
Shares Statistics:
A total of 54.53M shares are outstanding, with a floating share count of 32.77M. Insiders hold about 39.92% of the company’s shares, while institutions hold 62.30% stake in the company.
Earnings Estimates
The dynamic stock of Bicara Therapeutics Inc (BCAX) is currently being evaluated by a team of 5 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.56, with high estimates of -$0.38 and low estimates of -$0.69.
Analysts are recommending an EPS of between -$1.79 and -$2.75 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is -$2.52, with 5.0 analysts recommending between -$1.67 and -$2.97.
